Author/Authors :
Cazzaniga, M. E. Research Unit Phase I Trials - ASST Monza - Monza, Italy - Oncology Unit - ASST Monza - Monza, Italy , Cortesi, L. Haematology and Oncology Unit - Azienda Ospedaliero-Universitaria Policlinico di Modena - Modena, Italy , Ferzi, A. Oncology Unit - ASST Ovest Milanese - Legnano, Italy , Scaltriti, L. Oncology Day Hospital Unit - Ospedale Civile di Guastalla - Guastalla, Italy , Cicchiello, F. Oncology Unit - ASST Monza - Monza, Italy , Ciccarese, M. Oncology Unit - Ospedale Vito Fazzi - Lecce, Italy , Torre, S. Della Oncology Unit - ASST Rhodense-Presidio di Garbagnate Milanese e Presidio di Rho - Garbagnate, Italy , Villa, F Oncology Unit - ASST Lecco - Lecco, Italy , Giordano, M. Oncology Unit - ASST Lariana - Como, Italy , Verusio, C. Oncology Unit - ASST della Valle Olona - Saronno, Italy , Nicolini, M. Oncology Day Hospital Unit - Azienda USL Romagna - Cattolica, Italy , Gambaro, A. R. Oncology Unit - ASST Fatebenefratelli-Sacco - Milano, Italy , Zanlorenzi, L. Oncology Unit - ASST della Valle Olona - Busto Arsizio, Italy , Biraghi, E. Oncology Unit - ASST Melegnano-Martesana - Gorgonzola, Italy , Casini, E. Oncology Unit - ASST Monza - Monza, Italy , Legramandi, L. Methodology for Clinical Research Laboratory - IRCCS Istituto di Ricerche Farmacologiche Mario Negri - Milano, Italy , Rulli, E. Methodology for Clinical Research Laboratory - IRCCS Istituto di Ricerche Farmacologiche Mario Negri - Milano, Italy
Abstract :
Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.
